- Home
- HL vs JAZZ Comparison
HL vs JAZZ Comparison
Compare HL & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HL | JAZZ |
|---|---|---|
| Founded | 1891 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.8B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | HL | JAZZ |
|---|---|---|
| Price | $18.65 | $167.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 15 |
| Target Price | $11.14 | ★ $199.20 |
| AVG Volume (30 Days) | ★ 17.8M | 1.6M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.08% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | $1,224,563,000.00 | ★ $4,157,832,999.00 |
| Revenue This Year | $43.45 | $6.00 |
| Revenue Next Year | $15.89 | $6.84 |
| P/E Ratio | $60.76 | ★ N/A |
| Revenue Growth | ★ 45.62 | 4.14 |
| 52 Week Low | $4.46 | $95.49 |
| 52 Week High | $20.19 | $182.99 |
Technical Indicators
Market Signals| Indicator | HL | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 67.24 | 57.75 |
| Support Level | $15.84 | $161.00 |
| Resistance Level | $17.48 | $168.69 |
| Average True Range (ATR) | 1.11 | 4.96 |
| MACD | 0.20 | -1.99 |
| Stochastic Oscillator | 79.00 | 30.32 |
Price Performance
Historical ComparisonAbout HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc, and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, and Casa Berardi. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada, the United States, and Mexico, and it derives a majority of its revenue from the United States.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.